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Background: To analyze the characteristics and outcomes of women with breast cancer in the Northern Alberta
Health Region (NAHR) who declined recommended primary standard treatments.
Methods: A chart review was performed of breast cancer patients who refused recommended treatments during
the period 1980 to 2006. A matched pair analysis was performed to compare the survival data between those who
refused or received standard treatments.
Results: A total of 185 (1.2%) patients refused standard treatment. Eighty-seven (47%) were below the age of 75 at
diagnosis. The majority of those who refused standard treatments were married (50.6%), 50 years or older (60.9%),
and from the urban area (65.5%). The 5-year overall survival rates were 43.2% (95% CI: 32.0 to 54.4%) for those who
refused standard treatments and 81.9% (95% CI: 76.9 to 86.9%) for those who received them. The corresponding
values for the disease-specific survival were 46.2% (95% CI: 34.9 to 57.6%) vs. 84.7% (95% CI: 80.0 to 89.4%).
Conclusions: Women who declined primary standard treatment had significantly worse survival than those who
received standard treatments. There is no evidence to support using Complementary and Alternative Medicine
(CAM) as primary cancer treatment.Background
Breast cancer is the second leading cause of cancer-related
death (14%) among Canadian women, with an estimated
23,400 new cases and 5,100 deaths in 2011.1 In Canada, 1
in 9 (11%) women is expected to develop breast cancer
during their lifetime, and 1 in 29 (4%) die of it [1]. Breast
cancer management involves either modified radical mast-
ectomy (MRM) or breast conservation surgery (BCS) as
the primary treatment modality followed by adjuvant
treatments based on pathological characteristics. A 20-
year update of the National Surgical Adjuvant Breast and
Bowel Project (NSABP) study reported an overall survival
benefit of 45–49% among women treated with mastec-
tomy, and 44–48% survival benefit for those underwent
lumpectomy and breast irradiation [2]. In case of locally
advanced or inoperable breast cancer, neoadjuvant chemo-
therapy or radiotherapy has been considered for downsiz-
ing and downstaging the tumor. Kuerer et al. reported an* Correspondence: kurian.joseph@albertahealthservices.ca
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reproduction in any medium, provided the oroverall 5-year survival rate of 82% and 66%, respectively,
when segmental mastectomy with axillary dissection or
modified radical mastectomy was used, following neoadju-
vant chemotherapy [3].
Despite all efforts of the physicians, some patients may
decline the offered standard treatments. Although a
patient’s decision to refuse cancer treatment may be hard
to accept by the physician, this option is well within their
rights. Women with a diagnosis of breast cancer can re-
fuse their treatment partly or completely. The reasons for
such decisions could be multifactorial. Little attention is
devoted to understanding why and when cancer patients
refuse their offered treatment modalities. Information in
the literature is scanty too. This population-based study
analyzes the characteristics and outcomes of women with
breast cancer in the Northern Alberta Health Region
(NAHR) who refused recommended primary standard
treatments. Insights gained would be extremely useful in
the clinic.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Demographics and characteristics of women
diagnosed with breast carcinoma in the NAHR and
refused primary standard treatment, 1980–2006
Total number of women diagnosed with breast carcinoma 15,427
Women who refused primary standard treatment 185 (1.2%)
Women of age <75 years at diagnosis
among those who refused primary standard treatment
87 (47.0%)
Characteristics of women (age <75 years at diagnosis)
who refused primary standard treatment
n =87 (%)
Age at diagnosis
Less than 50 years 34 (39.1)




















Causes of death (n= 66)
Metastatic breast cancer 61 (70.1)
Other 5 (5.8)
NAHR: Northern Alberta Health Region.
CAM: Complementary & alternative medicine.
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Data
This is a retrospective chart review of patients diagnosed
with breast cancer in the NAHR, during the period 1980
to 2006, who refused the standard treatment recommen-
dations and were retrieved from the population-based
Alberta Cancer Registry (ACR) following approval from
the research ethics board. Any patient who has com-
pletely refused the recommended standard primary
treatment plan following biopsy confirmation of breast
cancer is considered as refusal of standard treatment.
Primary treatment could be surgery, neoadjuvant radio-
therapy or chemotherapy. Patients who refused adjuvant
treatments following surgery were not included in this
analysis. We also excluded patients older than 75 years
in our study as they have generally been eliminated
from clinical studies and active treatment regimens
(e.g., chemotherapy) in the past. The following data were
compiled by chart review: patient’s demographics at diag-
nosis, tumor characteristics, initial clinical and pathologic
stages, available details of any other treatment received, all
recurrence/relapse details and treatments received, date of
last contact or follow-up, and disease status if alive or date
and cause of death.
Statistical analysis
Demographics and characteristics of the study patients
are reported. A matched analysis was performed to com-
pare the outcome between patients who refused the
recommended treatment and those who received stand-
ard primary treatment during the study period. To
maximize the statistical power, the matching ratio was
set to 5:1; i.e., against each refusal five non-refusals are
selected. The matching variables were: age (± 3 years),
calendar year and clinical stage at diagnosis. Specific
tumor node metastasis (TNM) variables were not used
for matching since the majority of the patients had bi-
opsy confirmation only. A p-value ≤ 0.05 was considered
statistically significant.
We compared the survival between groups using the
Kaplan-Meier survival method. All the analyses were
completed in SAS software version 9.1 (SAS Institute,
NC, USA).
Results
The demographics of the patients who refused standard
surgical treatments in the NAHR during the period
1980–2006 are listed in Table 1. A total of 185 (1.2%)
patients refused the recommended standard primary
treatment in the NAHR. Of them, 87 (47%) were below
the age of 75 at the time of diagnosis.
The majority of the women who refused standard
treatments were married (50.6%), 50 years and older
(60.9%), and urban residents (65.5%) at the time ofdiagnosis. Among the retired group of patients, 10.4%
refused the standard treatment.
Table 2 describes the stage of disease at initial presen-
tation and disease status on referral to the tertiary can-
cer center. Fifty-seven patients (65.5%) had biopsy
confirmation only; 30 (34.5%) underwent delayed sur-
gery. Fifty patients (58%) decided to undergo comple-
mentary and alternative medicine (CAM) treatments,
whereas the reason for refusal was unclear for 37
(42.5%) patients. There was on average a delay of 20–
30 weeks before surgery.
Figure 1 compares the survival curves of patients who
refused and accepted treatments. The 5-year overall sur-
vival was 43.2% (95% CI: 32.0 to 54.4%) for those who
refused standard treatments and 81.9% (95% CI: 76.9 to
Table 2 Stage of disease at initial presentation and status of disease on referral to the tertiary cancer center, among






Number of patients by stage of disease
Number of patients
(n=87)
Duration of CAM therapy or





Biopsy only (n= 57)
I (including DCIS) 16 62 (41–101) II/III A/B (6)
II 22 Unknown IV
III 19 Unknown IV
IV 0 Unknown -
Unknown patients do not return for follow-up evaluation; CAM complementary and alternative medicine; RT radiotherapy; CT chemotherapy range (= difference
between maximum and minimum values).
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values for the disease-specific survival were 46.2% (95%
CI: 34.9 to 57.6%) vs. 84.7% (95% CI: 80.0 to 89.4%).
Since 58% of patients received different kinds of CAM,
a comparison of the outcome was performed between
groups who received CAM and those whose treatment
details were not known. Figure 2 compares the survival
patterns of women who refused treatment who either
received CAM or for whom the reason for refusal was
unknown. The 5-year overall survival was 57.4% (95%
CI: 42.7 to 72.1%) for women who received CAM and
26.3% (95% CI: 11.3 to 41.3%) for those whose treatment
details were unknown. The global survival for the CAM
group was better than for women whose reason for re-
fusal was unknown (p ≤ 0.05), and disease-specific sur-
vival for the CAM was better for women whose reason
for refusal was unknown, but this was not statistically
significant (31.5%; 95% CI: 15.1 to 48.0%).
Discussion
Our study was designed to quantify the incidence and
characteristics of breast cancer patients who refused
standard treatments offered in the NAHR and toFigure 1 Survival of the breast cancer patients who received standard
1980–2006. (a) All causes of deaths and (b) deaths due to breast canccompare their outcomes with those who received the
recommended treatments. At present, a reasonable esti-
mate of the incidence of patients refusing standard breast
cancer treatments is not available. Verkooijen et al.
reported that 0.7% of the breast cancer patients registered
at the Geneva cancer registry had declined any of the
standard treatments offered [4,5]. The disease-specific sur-
vival was significantly lower for this group of patients
when compared to those who received standard treatment
(36% vs. 75% at 10 years). Our data showed that 1.2%
breast cancer patients refused standard treatments with
similarly poor outcomes (43.2% vs. 81.9%).
A patient’s decision to decline the recommended can-
cer treatment depends on many factors, probably based
on previous experiences and personal values [6]. Various
factors claimed to be associated with cancer treatment
refusal include: lower social class, higher education, sin-
gle or divorced, patients living in a rural community,
higher age group, medical co-morbidity, fear of surgery,
fear of anesthesia and fear of treatment-related side
effects [4-7]. No significant association was linked to our
population, and fewer incidences occurred among the
retired group. The majority of our cohort was 50 yearstreatment compared to those who refused treatment in NAHR,
er only.
Figure 2 Survival of the breast cancer patients who took CAM compared to those who did not take CAM in NAHR, 1980–2006; (a) all
causes of deaths and (b) deaths due to breast cancer only.
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Our study did not reveal any factors closely related to
cancer treatment refusal.
Growing numbers of patients globally are integrating
non-standard treatments such as herbal medicines, vita-
mins, special diets, prayers, etc., into their cancer care.
These non-standard treatments are considered comple-
mentary and alternative medicine (CAM). One of the
interesting observations was that the majority of our
patients who refused the standard treatments received
various types of CAM. Unfortunately, the details of
CAM received by our patients were not available, since
most of these patients refused to be followed up. In our
series, most of the patients failed to report back for
follow-up once they decided to refuse surgery. There is
widespread concern among oncologists regarding the
use of CAM for cancer treatment as primary or support-
ive medication because of the lack of quality data sup-
porting its clinical efficiency. Patients may be aware of
the concerns felt by their oncologist regarding the use of
CAM, and hence such patients are often reluctant to
disclose information on the type of therapies they seek.
Kremser et al. reported that a significant proportion
(87.5%) of women with breast cancer use complemen-
tary therapies as supportive treatment [8]. Although
some benefits of CAM as a supportive treatment have
been reported, most evidence demonstrates that CAM is
ineffective or could adversely interact with standard can-
cer treatment [8].
Our data showed that almost all the patients who ini-
tially refused treatment progressed to a higher stage on
later presentation at the cancer center. The majority of
the patients (57%) in our series initially chose CAM as
the primary treatment instead of surgery. Those who
had chosen CAM had disease progression with particu-
larly poor disease-specific survival when compared to
those who received standard treatment. It is therefore
important to educate patients who decided to declinestandard treatments for CAM about the risk of such
therapies. There could be many reasons for a patient to
decline the standard treatment offered. However, a deci-
sion to refuse a possible curative treatment could lead to
an ethical dilemma for the physician. In general, the on-
cologist may respect a patient’s decision and disengage
with them. However, this may not be in the best interest
of the patient. Carrese et al. recommended evaluating
the patient’s capacity for decision-making and exploring
the potential risk factors influencing the decision to re-
fuse treatment [9]. Most patients appreciate effective
and open communication by the oncologist, which is es-
sential for better decisions and outcomes. Family physi-
cians (FPs) can also play significant roles in the decision-
making concerning their patient’s cancer treatment,
since most of them have long, trusting relationships with
their patients. In general, oncologists provide detailed in-
formation to the FPs about their patient’s treatment plan
after the initial consultation. FPs can provide emotional
support and educate the patient about the disease and
the nature of treatment needed.
This study was discussed at the Canadian Radiation
Oncologist’s (CARO) 2011 annual meeting, especially
the role of the involved oncologist in managing patients
who refuse cancer treatment. In general, the forum
agreed on the need for carefully educating the patient
directly and through the FP about the risks of taking
CAM instead of evidence-based treatments as primary
treatment. Such discussions could lead to reversal of
patient’s decision to refuse treatment. Open communica-
tion between the physician and patient is important.
Poor communication was mentioned as a reason for de-
clining conventional treatment [10]. Psychosocial ser-
vices can also help to bridge the communication gap and
resolve any misunderstanding of treatment options. In
our study, surgery was delayed an average of 20–30 weeks
because of initial treatment with CAM. Patients could be
interested in experiencing the benefits of trying CAM
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sult in a cure. The physician should emphasize the im-
pact of delaying radical treatment, with the risk of
forfeiting the possibility of conservative surgery, or in-
creasing nodal or distant cancer spread.
A potential limitation of our study was that it was a
retrospective series with a relatively small sample size. In
addition, the study lacked co-morbidity information as
well as detailed information on non-standard treatments
received by each patient.
Conclusions
In summary, women who refused evidence-based treat-
ment for breast cancer had significantly worse outcomes
than women who received standard therapies. At
present, there is no evidence available to support the use
of CAM as the primary breast cancer treatment. It is
therefore important for the physician to educate patients
about the treatments and also to warn about the poten-
tial risk of using CAM instead of undergoing evidence-
based treatment.
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